Clinical Trial Update: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Salmeterol/Fluticasone 50/500 mcg inhalation powder via Capsair vs Seretide Diskus 500 mcg in COPD; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Salmeterol/Fluticasone 50/500 mcg inhalation powder via Capsair (salmeterol/fluticasone)
• Seretide Diskus 500 mcg inhalation powder (salmeterol/fluticasone)

Snippet

Sponsor: Neutec Ar-Ge San ve Tic A.Ş | Conditions: COPD | Phase 4 | Status: TERMINATED